Napa Wealth Management Acquires New Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Napa Wealth Management bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 24,347 shares of the biopharmaceutical company's stock, valued at approximately $2,249,000. Gilead Sciences accounts for 1.0% of Napa Wealth Management's holdings, making the stock its 23rd largest position.

A number of other institutional investors also recently modified their holdings of GILD. HHM Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC lifted its stake in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. This represents a 9.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 25,429 shares of company stock worth $2,894,445 over the last ninety days. Company insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on GILD shares. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Oppenheimer dropped their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Royal Bank of Canada boosted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Price Performance

Shares of GILD stock traded up $2.16 during trading hours on Friday, reaching $102.50. 6,395,303 shares of the company were exchanged, compared to its average volume of 7,661,033. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The stock's fifty day moving average is $105.99 and its two-hundred day moving average is $99.58. The company has a market cap of $127.63 billion, a price-to-earnings ratio of 277.03, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period in the prior year, the business earned ($1.32) earnings per share. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.08%. Gilead Sciences's payout ratio is 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.